

30th January, 2019

The Dy. General Manager (Listing Dept.)
BSE Limited.,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Presentation to analysts on unaudited Consolidated Financial Results for the quarter and nine months ended 31st December, 2018

The presentation on unaudited Consolidated Financial Results for the quarter and nine months ended 31st December, 2018 to be made to analysts is enclosed for your records.

Thanking you,

Yours Sincerely,

For TORRENT PHARMACEUTICALS LIMITED



MAHESH AGRAWAL
VP (LEGAL) & COMPANY SECRETARY

Encl.: As above



Q3 & Ytd Dec FY 2018-19



Consolidated Revenues for Q3 2018-19

(₹ Crore)

Particulars	Q3 1819	Q3 1718	Gr%
India (Incl Unichem)	835	586	42%
US	490	266	84%
Brazil	168	194	-13%
Germany	267	227	18%
Other	171	131	31%
Others (Incl contract Mfg.)	120	59	103%
Total	2,051	1,463	40%



Consolidated Revenues for YTD Dec FY 2018-19

(` Crore)

Particulars	YTD 1819	YTD 1718	Gr%
India (Incl Unichem)	2,480	1,658	50%
US	1,217	793	54%
Brazil	483	495	-2%
Germany	770	626	23%
Other	500	389	28%
Others (Incl contract Mfg.)	367	281	31%
Total	5,817	4,242	37%

